Search

Your search keyword '"Tumors -- Drug therapy -- Genetic aspects"' showing total 8 results
Start Over Descriptor "Tumors -- Drug therapy -- Genetic aspects" Topic business
8 results on '"Tumors -- Drug therapy -- Genetic aspects"'

1. KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

Subjects
Medical research, Medicine, Experimental, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Genetic aspects, Clinical trials, Business, Business, international
Abstract

CAMBRIDGE, Mass. -- KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer [...]

Published
2021

2. Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Subjects
United States. Food and Drug Administration, Oncology, Experimental -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment -- Research, Business, News, opinion and commentary
Abstract

TAIPEI and SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of [...]

Published
2020

3. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Banking, finance and accounting industries, Business
Abstract

CRANBURY, N.J., Oct 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting [...]

Published
2020

4. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today [...]

Published
2020

5. Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

Subjects
United States. Food and Drug Administration, Tumors -- Drug therapy -- Genetic aspects, Epidermal growth factors -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Jul 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, [...]

Published
2020

6. Researchers at Sapporo Medical University School of Medicine Report New Data on Colon Cancer (Upregulation of adipocyte enhancer-binding protein 1 in endothelial cells promotes tumor angiogenesis in colorectal cancer)

Subjects
Protein binding -- Genetic aspects -- Reports, Cancer research -- Reports -- Genetic aspects, Endothelium -- Genetic aspects -- Reports, Tumors -- Drug therapy -- Genetic aspects, RNA sequencing -- Reports -- Genetic aspects, Colorectal cancer -- Genetic aspects -- Drug therapy, Business, Health, Health care industry
Abstract

2020 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology - Colon Cancer have been published. According to news reporting [...]

Published
2020

8. AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations

Subjects
Endothelial growth factors -- Genetic aspects, Tumors -- Drug therapy -- Genetic aspects, Lung tumors -- Drug therapy -- Genetic aspects, Cancer -- Care and treatment, Pharmaceutical industry -- Genetic aspects, Business, Business, international
Abstract

Preclinical Data Presented at International Lung Conference; Underscores Tivozanib Potency CAMBRIDGE, Mass. -- AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize [...]

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results